NEW Zealand's Pharmaceutical Management Agency PHARMAC has announced that it will fund the provision of shingles (herpes zoster) vaccine Zostavax from Merck Sharpe & Dohme, but the implementation will not take effect until 01 Apr next year.
The Australian Government has funded Zostavax by Seqirus through the National Immunisation Program from Nov 2016 to people aged 70 years, with a catch-up program for people aged 71--79 (PD 03 Nov 16).
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Nov 17